Stay updated on OP-1250 vs Standard in ER+/HER2- Advanced Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the OP-1250 vs Standard in ER+/HER2- Advanced Breast Cancer Clinical Trial page.

Latest updates to the OP-1250 vs Standard in ER+/HER2- Advanced Breast Cancer Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe webpage has undergone significant changes, including the removal of detailed descriptions of a clinical trial for palazestrant (OP-1250) and the addition of new drug names and identifiers related to breast cancer treatments.SummaryDifference14%
- Check30 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for March 11, 2025, while a date for March 25, 2025, has been removed.SummaryDifference0.2%
- Check37 days agoChange DetectedThe page has been updated to reflect a new last update date of March 25, 2025, and a revision change to version 2.14.3, replacing the previous date of March 11, 2025, and version 2.14.2.SummaryDifference0.1%
- Check52 days agoChange DetectedThe webpage has updated its date references, removing past dates from late 2024 and adding new dates in March 2025.SummaryDifference0.6%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1.0%
Stay in the know with updates to OP-1250 vs Standard in ER+/HER2- Advanced Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the OP-1250 vs Standard in ER+/HER2- Advanced Breast Cancer Clinical Trial page.